# SH-OLIGOPEPTIDE-1 (sh-oligopeptide-1) — Global Cosmetic Regulatory & Formulation Monograph

- **Canonical URL**: https://www.inciname.com/en/ingredients/sh-oligopeptide-1
- **Standard INCI**: `SH-OLIGOPEPTIDE-1`
- **KR MFDS Standard Name**: `에스에이치-올리고펩타이드-1`
- **CAS No.**: `N/A`
- **EC / EINECS No.**: `N/A`
- **Origin**: `peptide`
- **Functions**: 피부컨디셔닝제
- **Molecular Formula / MW**: `C257H379N73O83S7 (53 amino acids)` (6200 g/mol)

## 1. 7-Track Official Regulatory Label Names
| Track | Official Label Nomenclature |
| :--- | :--- |
| KR (MFDS Standard) | 에스에이치-올리고펩타이드-1 |
| KR (Former Names) | — |
| EU (CosIng 1223/2009) | SH-OLIGOPEPTIDE-1 |
| US (PCPC / MoCRA INCI) | SH-OLIGOPEPTIDE-1 |
| US (FDA OTC Monograph) | — |
| CN (NMPA IECIC) | — |
| JP (JCIA / MHLW QD) | SH-OLIGOPEPTIDE-1  |

## 2. Layer 1 — Global 6-Region Statutory Summary
- **KR (MFDS)**: `restricted`
- **EU (1223/2009)**: `none`
- **US (FDA/MoCRA)**: `none`
- **CN (NMPA IECIC)**: `none` (Entry: `—`)
- **JP (MHLW)**: `none`
- **ASEAN (ACD)**: `none`



## 3. Layer 2 — Toxicological & Historical Safe Use Concentrations
- Listed within general cosmetic GMP safety thresholds.

## 4. Layer 3 — Formulation Quartiles & Compatibility
- **Optimal pH Window**: 5.5 – 7.2
- **Max Process Temp**: ≤ 40°C
- **Synergy Pairings**: HYDROGENATED LECITHIN, SODIUM HYALURONATE, PANTHENOL, SH-POLYPEPTIDE-1
- **Incompatibilities**: Denatures rapidly above 45°C, at pH < 5.0, or in the presence of proteases, strong acids, or >10% ethanol; use Hydrogenated Lecithin nanoliposome encapsulated grade

## 5. Academic Monograph
■ [1. Chemical Identity & International Labeling Nomenclature]
  - INCI Name: SH-OLIGOPEPTIDE-1 | CAS No.: N/A | EC No.: N/A
  - Origin: PEPTIDE | Functions: Skin Conditioning
  - Physicochemical Profile: Formula C257H379N73O83S7 (53 amino acids) | MW 6200.0 g/mol | /   | Ionic Nature: amphoteric | CosIng/MFDS 
  - Official Regional Label Names: US [SH-OLIGOPEPTIDE-1] · EU [SH-OLIGOPEPTIDE-1] · CN [-] · JP [-] · JP Quasi-Drug [-]
■ [2. Dermatological Mechanism of Action & Functional Role]
  - sh-Oligopeptide-1 is a single chain recombinant human peptide, produced by fermentation in E. coli. The starting gene is synthesized to be identical to the human gene which codes for Epidermal Growth Factor. It contains a maximum of 53 amino acids which may contain disulfide bonds and/or sugar. The protein consists of the proper sequence of the standard amino acids Classified under origin 'peptide', it acts within the cosmetic vehicle or stratum corneum to deliver  performance and structural formulation stability.
■ [3. Global 6-Jurisdiction Regulatory Status & Safety Limits (Layer 1 & Layer 2)]
  - Regional Summary: KR: RESTRICTED | EU: NONE | US: NONE | CN: NONE | JP: NONE | ASEAN: NONE (CN IECIC (2025) Entry No. Unlisted (-))
  - [KR / COMPOSITION / limited] (Max 0.001%): 
  - Official Safety & Historical Use Concentration (Layer 2): Quantum satis (QS) within standard cosmetic safety margins
■ [4. Formulation Dosage Guide by Product Category (Layer 3-A)]
  - [aqueous_serum] Typical range: 0.0001 ~ 0.002% (Median 0.0005%, Ref: PubMed EGF Wound Healing & CosIng Monograph) — Epidermal Growth Factor (EGF) receptor agonist for cellular renewal (1~20 ppm)
■ [5. Formulation Engineering, Stability & Incompatibility Matrix (Layer 3-B)]
  - Addition Phase: Final Cool-down Phase (< 38°C; Gentle stirring)
  - Optimal pH Range: pH 5.5 ~ 7.2 | Max Process Temp: Max 40°C | Electrolyte Tolerance: LOW
  - Incompatibility / Caution: Denatures rapidly above 45°C, at pH < 5.0, or in the presence of proteases, strong acids, or >10% ethanol; use Hydrogenated Lecithin nanoliposome encapsulated grade
  - Synergy Pairings: HYDROGENATED LECITHIN, SODIUM HYALURONATE, PANTHENOL, SH-POLYPEPTIDE-1 | Reference Trade Names: Nano-EGF Liposome, rh-Oligopeptide-1
■ [6. Peer-Reviewed Literature & Official Compendia Evidence]
  - PMID 41294565 (2025, Gels): Update on the Research of an Emulgel for the Effective Treatment of Atopic Dermatitis: Clinical Investigation in Childre
  - PMID 37452558 (2023, Cutan Ocul Toxicol): Topical application of sh-oligopeptide-1 and clinical trials with cosmetic preparations: risk or fraud?
  - PMID 37784053 (2023, BMC Musculoskelet Disord): A pre-market interventional, single-arm clinical investigation of a new topical lotion based on hyaluronic acid and pept

## 6. Linked PubMed Literature
- [PMID: 41294565] Update on the Research of an Emulgel for the Effective Treatment of Atopic Dermatitis: Clinical Investigation in Children — *Gels* (2025)
- [PMID: 37452558] Topical application of sh-oligopeptide-1 and clinical trials with cosmetic preparations: risk or fraud? — *Cutan Ocul Toxicol* (2023)
- [PMID: 37784053] A pre-market interventional, single-arm clinical investigation of a new topical lotion based on hyaluronic acid and peptides, EGYFIL(TM), for the treatment of pain and stiffness in soft tissues — *BMC Musculoskelet Disord* (2023)